Singapore markets closed

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.3500+0.0600 (+2.62%)
At close: 04:00PM EST
2.4500 +0.10 (+4.26%)
After hours: 04:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.2900
Open2.4514
Bid2.2700 x 900
Ask2.4900 x 1000
Day's range2.2500 - 2.4514
52-week range2.2000 - 10.8800
Volume65,430
Avg. volume176,803
Market cap62.132M
Beta (5Y monthly)2.41
PE ratio (TTM)N/A
EPS (TTM)-0.7720
Earnings date08 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est18.20
  • Business Wire

    DiaMedica Therapeutics to Present Research at International Stroke Conference

    MINNEAPOLIS, January 25, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 – 11, 2022. For information about the event, visit: https://professional.heart.org/en/meetings/int

  • Business Wire

    DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

    MINNEAPOLIS, January 05, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Kirsten Gruis, M.D. as Chief Medical Officer. Dr. Gruis is a board-certified neurologist with 20 years of experience in both clinical medicine and drug development in large and small biopharmaceutical companies.

  • Business Wire

    DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event

    MINNEAPOLIS, December 13, 2021--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually from January 5-7, 2022.